


Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound of Formula (I):



wherein:

~~W and Y are independently~~ is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond[[],] or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

Y is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

X is -NR<sub>3</sub>C(O)-, -C(O)NR<sub>3</sub>, -NR<sub>3</sub>S(O)<sub>2</sub>-, -S(O)<sub>2</sub>NR<sub>3</sub>-,  
-NR<sub>3</sub>C(O)NR<sub>4</sub>-, -NR<sub>3</sub>C(O)O-, -OC(O)NR<sub>3</sub>-, -NR<sub>3</sub>-, -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)<sub>2</sub>-;

R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1-4</sub> alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

R<sub>1</sub> is H, hydroxyl, halogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sub>2</sub> is H or C<sub>1-8</sub> alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

i) — when both R<sub>1</sub> and R<sub>2</sub> are H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H, C(O)-C<sub>6</sub>H<sub>4</sub>-p-O-C<sub>8</sub>H<sub>17</sub>, OCH<sub>2</sub>CH<sub>3</sub>, OH, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H, CH<sub>2</sub>CO<sub>2</sub>H and CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>H;

ii) — when R<sub>1</sub> is CH<sub>3</sub> and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH<sub>2</sub>CO<sub>2</sub>H, C(O)CH=CH-C<sub>6</sub>H<sub>5</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-p-OCH<sub>3</sub>, CO<sub>2</sub>H, C(O)CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-o-CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-o-Br, C(O)C<sub>6</sub>H<sub>4</sub>-o-Cl, and C(O)C<sub>6</sub>H<sub>5</sub>;

iii) — when R<sub>1</sub> is Br and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H;

iv) — when R<sub>1</sub> is OH and R<sub>2</sub> is H then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>H;

v) — when R<sub>1</sub> is H and R<sub>2</sub> is CH<sub>3</sub> then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy, C(O)NH-C<sub>6</sub>H<sub>4</sub>-p-OCH<sub>2</sub>CH<sub>3</sub>, NHC(O)CH(CH<sub>3</sub>)<sub>2</sub>, SCH<sub>3</sub>, C(O)-C<sub>6</sub>H<sub>4</sub>-p-O-C<sub>8</sub>H<sub>17</sub>, SCH<sub>2</sub>CH<sub>3</sub>, C(O)NHC<sub>6</sub>H<sub>5</sub>, CH(OCH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>OC(O)CH<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-p-NO<sub>2</sub>, C(O)C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub> and CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>;

vi) — when R<sub>1</sub> is OH and R<sub>2</sub> is CH<sub>3</sub> then [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH<sub>2</sub>OCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CH<sub>2</sub>OCH(CH<sub>3</sub>)<sub>2</sub> and CH<sub>2</sub>OH;

vii) — when R<sub>2</sub> is CH<sub>3</sub> then:

R<sub>1</sub> is not CH<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not 2,6-dichloro-4-trifluoromethylphenoxy;

R<sub>1</sub> is not I and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>;

R<sub>1</sub> is not C(CH<sub>3</sub>)<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not formyl;

~~R<sub>1</sub> is not Br and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>CH<sub>3</sub>;~~

and

~~R<sub>1</sub> is not CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not formyl;~~

viii) when R<sub>1</sub> is H and R<sub>2</sub> is CH<sub>2</sub>CH<sub>3</sub>, then ~~[W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH<sub>2</sub>SCH<sub>2</sub>CH<sub>3</sub>, OCH<sub>2</sub>CH<sub>2</sub>CH=CH<sub>2</sub>, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>CHO, CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, OCH<sub>3</sub>, C(O)CH<sub>2</sub>Br, CO<sub>2</sub>C<sub>8</sub>H<sub>17</sub>, formyl, OH, CH<sub>2</sub>N(CH<sub>2</sub>CH<sub>2</sub>Cl)<sub>2</sub>, CH(CH<sub>3</sub>)OC(O)CH<sub>3</sub>, CH<sub>2</sub>OH, CH<sub>2</sub>OC(O)CH<sub>3</sub>, C(O)CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>5</sub> and C(O)NHCH<sub>2</sub>CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>.~~

ix) when R<sub>1</sub> is CH<sub>3</sub> and R<sub>2</sub> is CH<sub>2</sub>CH<sub>3</sub>, then ~~[W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CH(OH)C<sub>6</sub>H<sub>4</sub>-p-N(CH<sub>3</sub>)<sub>2</sub>, C(O)CH<sub>2</sub>C(O)CH<sub>3</sub>, CO<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, CO<sub>2</sub>CH<sub>3</sub>, C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-p-OCH<sub>3</sub>, C(O)C<sub>6</sub>H<sub>4</sub>-o-Br, C(O)C<sub>6</sub>H<sub>4</sub>-p-Cl, C(O)C<sub>6</sub>H<sub>4</sub>-o-Cl, C(O)CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub> and C(O)C<sub>6</sub>H<sub>5</sub>;~~

x) when R<sub>2</sub> is CH<sub>2</sub>CH<sub>3</sub>, then:

~~R<sub>1</sub> is not I and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;~~

~~R<sub>1</sub> is not CF<sub>3</sub> and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>; and~~

~~R<sub>1</sub> is not Br and [W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;~~

xi) when R<sub>1</sub> is OH and R<sub>2</sub> is CH<sub>2</sub>CH<sub>3</sub>, then ~~[W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not C(O)C<sub>6</sub>H<sub>5</sub>, C(O)NH<sub>2</sub> and CO<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>;~~

xii) when R<sub>1</sub> is H and R<sub>2</sub> is C(CH<sub>3</sub>)<sub>3</sub>, then ~~[W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not CO<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, C(O)NHC(O)CH<sub>3</sub> and C(O)NH<sub>2</sub>;~~

xiii) when R<sub>1</sub> is OH and R<sub>2</sub> is CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>3</sub>, then ~~[W]<sub>n</sub>-X-[Y]<sub>m</sub>-Z together is not C(O)C<sub>6</sub>H<sub>5</sub>; and~~

xiv) when X is NR<sub>3</sub>, then "n" is 1.

Claims 2-151 are cancelled.

152. (Currently Amended) The compound according to claim 1 wherein W is the straight or branched C<sub>1-5</sub> alkylene group optionally containing one double bond[[],] or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

153. (Currently Amended) The compound according to claim 152 wherein W is selected from the group consisting of -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH(CH<sub>3</sub>)CH<sub>2</sub>-, -CH<sub>2</sub>CH(CH<sub>3</sub>)-,

~~-C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~and -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>-~~,  
~~-CH(CH<sub>3</sub>)C(O)-~~, ~~C(O)CH(CH<sub>3</sub>)-~~, ~~CH<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>CH<sub>2</sub>-~~, ~~C(CH<sub>3</sub>)<sub>2</sub>C(O)-~~, ~~C(O)C(CH<sub>3</sub>)<sub>2</sub>-~~,  
~~C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~CH<sub>2</sub>C(O)CH<sub>2</sub>-~~, ~~CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~,  
~~CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-~~, ~~CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-~~, ~~CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-~~,  
~~CH=CHC(O)-~~, ~~C(O)CH=CH-~~, ~~C(CH<sub>3</sub>)=CHC(O)-~~, ~~and C(O)CH=C(CH<sub>3</sub>)-~~, each optionally substituted  
with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

154. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is ~~-CH(CH<sub>3</sub>)~~-,  
~~-CH(OCH<sub>3</sub>)CH<sub>2</sub>-~~, or ~~-CH<sub>2</sub>CH(OCH<sub>3</sub>)~~-, each optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or  
C<sub>1-4</sub> alkoxy.

155. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is selected from the  
group consisting of ~~-CH<sub>2</sub>-~~, ~~-CH(CH<sub>3</sub>)~~-, ~~-C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH(CH<sub>3</sub>)CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH(CH<sub>3</sub>)~~-,  
~~-C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~-CH(OCH<sub>3</sub>)CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH(OCH<sub>3</sub>)~~-, ~~-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~and -~~,  
~~CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>-~~, ~~CH(CH<sub>3</sub>)C(O)-~~, ~~C(O)CH(CH<sub>3</sub>)-~~, ~~CH<sub>2</sub>CH<sub>2</sub>C(O)-~~,  
~~C(O)CH<sub>2</sub>CH<sub>2</sub>-~~, ~~C(CH<sub>3</sub>)<sub>2</sub>C(O)-~~, ~~C(O)C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~CH<sub>2</sub>C(O)CH<sub>2</sub>-~~,  
~~CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-~~, ~~C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-~~,  
~~CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-~~, ~~CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-~~, ~~CH=CHC(O)-~~, ~~C(O)CH=CH-~~, ~~C(CH<sub>3</sub>)=CHC(O)-~~, ~~and~~  
~~C(O)CH=C(CH<sub>3</sub>)-~~.

156. (Currently Amended) The compound according to claim 1 ~~152~~ wherein W is ~~-CH=CH-[I,J]~~ or ~~-~~  
~~C≡C-~~, or ~~C(O)-~~.

157. (Previously Presented) The compound according to claim 1 wherein Y is the straight or branched  
chain C<sub>1-5</sub> alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein  
said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

158. (Currently Amended) The compound according to claim 1 ~~157~~ wherein Y is selected from the  
group consisting of ~~-CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH(CH<sub>3</sub>)CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH(CH<sub>3</sub>)~~-, ~~-C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-~~, ~~-~~  
~~CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~-CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-~~, ~~-C≡CCH<sub>2</sub>-~~, ~~-CH<sub>2</sub>C≡C-~~, ~~-CH<sub>2</sub>C(O)-~~, ~~-C(O)CH<sub>2</sub>-~~,

-CH(CH<sub>3</sub>)C(O)-, -C(O)CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>-, -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-,  
-CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)-, -C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)-, -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>-, -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>-,  
CH=CHC(O)-, -C(O)CH=CH-, -C(CH<sub>3</sub>)=CHC(O)-, and -C(O)CH=C(CH<sub>3</sub>)-, each optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

159. (Currently Amended) The compound according to claim 1 157 wherein Y is selected from the group consisting of -CH<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>- , -CH(CH<sub>3</sub>)CH<sub>2</sub>- , -CH<sub>2</sub>CH(CH<sub>3</sub>)- , -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -C≡CCH<sub>2</sub>- , -CH<sub>2</sub>C≡C- , -CH<sub>2</sub>C(O)- , -C(O)CH<sub>2</sub>- , -CH(CH<sub>3</sub>)C(O)- , -C(O)CH(CH<sub>3</sub>)- , -CH<sub>2</sub>CH<sub>2</sub>C(O)- , -C(O)CH<sub>2</sub>CH<sub>2</sub>- , -C(CH<sub>3</sub>)<sub>2</sub>CH<sub>2</sub>C(O)- , -C(O)CH<sub>2</sub>C(CH<sub>3</sub>)<sub>2</sub>- , -CH<sub>2</sub>C(O)CH<sub>2</sub>- , -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>C(O)- , -C(O)CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>- , -CH(CH<sub>3</sub>)CH<sub>2</sub>CH<sub>2</sub>C(O)- , -C(O)CH<sub>2</sub>CH<sub>2</sub>CH(CH<sub>3</sub>)- , -CH<sub>2</sub>CH<sub>2</sub>C(O)CH<sub>2</sub>- , -CH<sub>2</sub>C(O)CH<sub>2</sub>CH<sub>2</sub>- , CH=CHC(O)- , -C(O)CH=CH- , -C(CH<sub>3</sub>)=CHC(O)-, and -C(O)CH=C(CH<sub>3</sub>)-.

160. (Currently Amended) The compound according to claim 1 157 wherein Y is -CH(CH<sub>3</sub>)- optionally substituted with halogen, hydroxyl or C<sub>1-4</sub> alkoxy.

161. (Currently Amended) The compound according to claim 1 157 wherein Y is -CH(OCH<sub>3</sub>)CH<sub>2</sub>- or -CH<sub>2</sub>CH(OCH<sub>3</sub>)- optionally substituted with halogen, hydroxyl or C<sub>1-4</sub> alkyl.

162. (Currently Amended) The compound according to claim 1 157 wherein Y is -CH=CH- optionally substituted with C<sub>1-4</sub> alkyl or C<sub>1-4</sub> alkoxy.

163. (Currently Amended) The compound according to claim 1 ~~1457~~ wherein Y is -C(CH<sub>3</sub>)<sub>2</sub>-, -C≡C-, -C(O)-, -C(CH<sub>3</sub>)<sub>2</sub>C(O)-, or -C(O)C(CH<sub>3</sub>)<sub>2</sub>-.

164. (Previously Presented) The compound according to claim 1 wherein X is -NHC(O)- or -C(O)NH-.

165. (Previously Presented) The compound according to claim 1 wherein X is -NH- or -NCH<sub>3</sub>-.

166. (Currently Amended) The compound according to claim 1 wherein X is selected from the group consisting of -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)-, or -S(O)<sub>2</sub>-.

167. (Previously Presented) The compound according to claim 1 wherein Z is H, halogen, or phenyl.

168. (Previously Presented) The compound according to claim 1 wherein Z is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF<sub>3</sub>, -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub> and -OCF<sub>3</sub>.

169. (Previously Presented) The compound according to claim 1 wherein Z is heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, -CF<sub>3</sub>, -NHCH<sub>3</sub>, -N(CH<sub>3</sub>)<sub>2</sub>, -CH<sub>3</sub>, -CH<sub>2</sub>CH<sub>3</sub>, -OCH<sub>3</sub> and -OCF<sub>3</sub>.

170. (Previously Presented) The compound according to claim 1 wherein R<sub>1</sub> is H.

171. (Cancelled)

172. (Previously Presented) The compound according to claim 1 wherein R<sub>1</sub> is halogen.

173. (Previously Presented) The compound according to claim 1 wherein R<sub>1</sub> is C<sub>1-4</sub> alkyl.


174. (Previously Presented) The compound according to claim 1 wherein R<sub>1</sub> is C<sub>1-4</sub> haloalkyl.

175. (Previously Presented) The compound according to claim 1 wherein R<sub>2</sub> is H.
176. (Previously Presented) The compound according to claim 1 wherein R<sub>2</sub> is C<sub>1-8</sub> alkyl.
177. (Currently Amended) The according to claim 1 selected from the group consisting of:  
~~5-Ethylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-Ethanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-Ethanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Oxo-propoxymethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Prop-2-ynyloxymethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-Carbamoyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1,1-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Carboxy-1,1-dimethyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Acetoxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Chloro-3-hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Carboxy-1-methyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Propylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Amino-vinyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Amino-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Dimethylamino-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Hydroxy-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Carboxy-1-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Carboxy-vinyl)-1H-pyrazole-3-carboxylic acid;~~

5-(2-Methoxy-vinyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Acetoxy-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-Carbamoylmethyl 1H-pyrazole-3-carboxylic acid;~~  
~~5-Hydroxymethyl 1H-pyrazole-3-carboxylic acid;~~  
5-(2,2-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Imino-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Amino-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(Ethoxycarbonyl-fluoro-methyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Ethoxycarbonylmethyl 1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;  
~~5-(1-Methoxycarbonyl-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(1-Hydroxy-1-methoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Methoxycarbonyl-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(2-Methoxycarbonyl-vinyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-Dimethylcarbamoylmethyl 1H-pyrazole-3-carboxylic acid;~~  
~~1H-Pyrazole-3,5-dicarboxylic acid;~~  
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid;  
5-(2-Methoxy-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methoxy-propyl)-1H-pyrazole-3-carboxylic acid;  
5-Methylsulfanyl-methyl-1H-pyrazole-3-carboxylic acid;  
5-Methanesulfinyl-methyl-1H-pyrazole-3-carboxylic acid;  
5-Methanesulfonyl-methyl-1H-pyrazole-3-carboxylic acid;  
5-(2-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methylsulfanyl-propyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methanesulfinyl-propyl)-1H-pyrazole-3-carboxylic acid;  
5-(3-Methanesulfonyl-propyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Amino-ethyl)-1H-pyrazole-3-carboxylic acid;~~

5-(2-Methylamino-ethyl)-1H-pyrazole-3-carboxylic acid;  
5-(2-Dimethylamino-ethyl)-1H-pyrazole-3-carboxylic acid;  
~~5-(2-Oxo-propyl)-1H-pyrazole-3-carboxylic acid;~~  
~~5-(3-Oxo-butyl)-1H-pyrazole-3-carboxylic acid;~~  
5-(Benzylamino-methyl)-1H-pyrazole-3-carboxylic acid;  
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;  
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid; or  
5-(2,2-Diethoxy-ethyl)-1H-pyrazole-3-carboxylic acid; or  
a pharmaceutically acceptable salt, solvate or hydrate thereof.

178. (Currently Amended) A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (I):



wherein:

W and Y are independently is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond[[,]] or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

Y is a straight or branched chain C<sub>1-5</sub> alkylene group optionally containing one double bond, or one triple bond or carbonyl, wherein said C<sub>1-5</sub> alkylene group is optionally substituted with halogen, hydroxyl, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> haloalkyl or C<sub>1-4</sub> alkoxy;

X is -NR<sub>3</sub>C(O)-, -C(O)NR<sub>3</sub>, -NR<sub>3</sub>S(O)<sub>2</sub>-, -S(O)<sub>2</sub>NR<sub>3</sub>-,  
-NR<sub>3</sub>C(O)NR<sub>4</sub>-, -NR<sub>3</sub>C(O)O-, -OC(O)NR<sub>3</sub>-, -NR<sub>3</sub>-, -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or -S(O)<sub>2</sub>-;

R<sub>3</sub> and R<sub>4</sub> are independently H, C<sub>1-4</sub> alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C<sub>1-4</sub>

haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C<sub>1-4</sub> haloalkyl, amino, C<sub>1-4</sub> alkylamino, di-C<sub>1-4</sub>-alkylamino, C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>1-4</sub> haloalkoxy, C<sub>1-4</sub> alkylthio, C<sub>1-4</sub> alkylsulfinyl, C<sub>1-4</sub> alkylsulfonyl, C<sub>1-4</sub> haloalkylthio, C<sub>1-4</sub> haloalkylsulfinyl and C<sub>1-4</sub> haloalkylsulfonyl;

R<sub>1</sub> is H, hydroxyl, halogen, C<sub>1-4</sub> alkyl or C<sub>1-4</sub> haloalkyl;

R<sub>2</sub> is H or C<sub>1-8</sub> alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that when X is NR<sub>3</sub>, then "n" is 1.

179. (Previously Presented) A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 178.
180. (Previously Presented) The method according to claim 179 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.
181. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.
182. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia.

183. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is atherosclerosis.
184. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is coronary heart disease.
185. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is insulin resistance.
186. (Previously Presented) The method according to claim 180 wherein the metabolic-related disorder is type 2 diabetes.
187. (Previously Presented) The method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.